AVTX-803 is under clinical development by Avalo Therapeutics and currently in Phase III for Inherited Metabolic Disorders. According to GlobalData, Phase III drugs for Inherited Metabolic Disorders have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AVTX-803’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVTX-803 is under development for the treatment of leukocyte adhesion deficiency type II (LADII) or congenital disorder of glycosylation type IIc in pediatrics. It is a L-fucose. The therapeutic candidate is a genetically-targeted, substrate replacement therapy administered orally.
Avalo Therapeutics overview
Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics’ prescription medications comprise aciphex sprinkle, cefaclor, millipred tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.
For a complete picture of AVTX-803’s drug-specific PTSR and LoA scores, buy the report here.